Literature DB >> 1555897

Use of multi-cell spheroids of ovarian carcinoma as an intraperitoneal radio-immunotherapy model: uptake, retention kinetics and dosimetric evaluation.

M Bardiès1, P Thedrez, J F Gestin, B M Marcille, D Guerreau, A Faivre-Chauvet, M Mahé, C Sai-Maurel, J F Chatal.   

Abstract

The purpose of this study, using multi-cell spheroids as an in vitro model of micrometastases of ovarian carcinoma for i.p. radio-immunotherapy, was to measure the uptake and retention kinetics of 111In-labeled F(ab')2 fragments of OC125 monoclonal antibody (MAb) in spheroids of the NIH:OVCAR-3 cell line and to estimate absorbed doses with beta-emitting radionuclides (kinetics was assumed to be similar to that of indium-111). With 0.2-mm-diameter spheroids at different MAb concentrations the highest binding value was determined. Retention kinetics showed a biological half-life of 50 hr. These data were used to calculate absorbed doses by integration of Berger's latest-point kernels. Mean absorbed doses when spatial distribution was considered to be uniform at the surface (no penetration) or throughout the spheroid (total penetration) were, respectively, 247 and 417 Gy with 153Sm, and 90 and 135 Gy with 90Y. Thus, the use of a similar MAb concentration and specific activity in patients should lead to high absorbed doses in i.p. radio-immunotherapy of micrometastases.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1555897     DOI: 10.1002/ijc.2910500627

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  8 in total

1.  Initial formation of IGROV1 ovarian cancer multicellular aggregates involves vitronectin.

Authors:  Sabrina Kellouche; Julien Fernandes; Johanne Leroy-Dudal; Olivier Gallet; Soizic Dutoit; Laurent Poulain; Franck Carreiras
Journal:  Tumour Biol       Date:  2010-02-24

2.  Beta 1-integrins regulate the formation and adhesion of ovarian carcinoma multicellular spheroids.

Authors:  R C Casey; K M Burleson; K M Skubitz; S E Pambuccian; T R Oegema; L E Ruff; A P Skubitz
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

3.  Ovarian carcinoma spheroids disaggregate on type I collagen and invade live human mesothelial cell monolayers.

Authors:  Kathryn M Burleson; Linda K Hansen; Amy P N Skubitz
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

4.  Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters.

Authors:  A Neshasteh-Riz; W J Angerson; J R Reeves; G Smith; R Rampling; R J Mairs
Journal:  Br J Cancer       Date:  1997       Impact factor: 7.640

5.  Approach for chemosensitization of cisplatin-resistant ovarian cancer by cucurbitacin B.

Authors:  Fardous F El-Senduny; Farid A Badria; Ahmed M El-Waseef; Subhash C Chauhan; Fathi Halaweish
Journal:  Tumour Biol       Date:  2015-08-05

6.  Disaggregation and invasion of ovarian carcinoma ascites spheroids.

Authors:  Kathryn M Burleson; Matthew P Boente; Stefan E Pambuccian; Amy P N Skubitz
Journal:  J Transl Med       Date:  2006-01-24       Impact factor: 5.531

7.  The selection of antibodies for targeted therapy of small-cell lung cancer (SCLC) using a human tumour spheroid model to compare the uptake of cluster 1 and cluster w4 antibodies.

Authors:  Y Olabiran; J A Ledermann; N J Marston; G M Boxer; R Hicks; R L Souhami; S G Spiro; R A Stahel
Journal:  Br J Cancer       Date:  1994-02       Impact factor: 7.640

8.  Targeted alpha therapy approach to the management of pancreatic cancer.

Authors:  Barry J Allen; Syed M Abbas Rizvi; Chang F Qu; Ross C Smith
Journal:  Cancers (Basel)       Date:  2011-04-01       Impact factor: 6.639

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.